Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

Inclusion Criteria: * Donor meets MGH transplant center criteria and already listed for isolated kidney transplant * No available living kidney donor * Recipient has ≤ 730 days of accrued transplant waiting time * Recipient chronic hemodialysis or peritoneal dialysis * Recipient must agree to birth control. °.Weigh ≥ 50kg * Serum ALT within normal limits * Subject's Insurance company approves payment for DAA therapy post-kidney transplant Exclusion Criteria: * AB Blood type * HCV genotype 1 * BMI \> 35 * Any liver disease in recipient * Pregnant or nursing (lactating) women * Known allergy or intolerance to tacrolimus that would require administration of cyclosporine * Albumin \< 3g/dl or * Platelet count \< 75 x 103/mL * Positive crossmatch or positive donor specific antibodies * HCV RNA positive * Hepatitis B surface antigen positive * Patients with primary focal segmental glomerulosclerosis (FSGS) * Any contra-indication to kidney transplantation per our center protocol